Meeting
2023 ASCO Annual Meeting
Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.
Authors
Mehdi Brahmi
Centre Léon-Bérard, Lyon, France
Mehdi Brahmi , Olivier Tredan , Nicolas Penel , Christine Chevreau , Christophe Perrin , Nelly Firmin , Emmanuelle Bompas , Francois Bertucci , Valéry Attignon , Pierre Saintigny , Isabelle Treilleux , Sylvie Chabaud , Gwenaelle Garin , David Pérol , Jean-Yves Blay , Armelle Dufresne
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Clinical Trial Registration Number
NCT03163732
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 11545)
DOI
10.1200/JCO.2023.41.16_suppl.11545
Abstract #
11545
Poster Bd #
479
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Kim N. Chi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer.
First Author: Keun-Wook Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The Endoscopic Ultrasound Molecular Analysis of Pancreatic Cancer (EUMEPC) study.
First Author: Joanne Lundy
Poster
2022 ASCO Annual Meeting
Molecular alterations associated with rapid progression following CDK4/6 inhibitors (CDKi) in metastatic hormone receptor–positive breast cancer (mHRBC).
First Author: Malinda T West